Detalhe da pesquisa
1.
HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors.
BMC Vet Res
; 9: 130, 2013 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23816051
2.
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.
Eur J Nucl Med Mol Imaging
; 37(1): 93-102, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19593562
3.
First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent.
Anticancer Res
; 26(4B): 2841-8, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16886603
4.
Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology.
In Vivo
; 20(3): 325-31, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16724665
5.
Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma.
PLoS One
; 11(10): e0165382, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27776176
6.
Primary bone cancer in Leonbergers may be associated with a higher bodyweight during adolescence.
Prev Vet Med
; 119(1-2): 48-53, 2015 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25732913
7.
Breed-specific incidence rates of canine primary bone tumors--a population based survey of dogs in Norway.
Can J Vet Res
; 75(3): 209-15, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22210997
8.
Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976-2005).
Cancer Epidemiol Biomarkers Prev
; 20(8): 1770-7, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21724855
9.
Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
Blood
; 110(6): 2049-56, 2007 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17536011
10.
A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas.
Int J Cancer
; 100(4): 476-9, 2002 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12115533